Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aspirin dose comparison for prevention of pre-eclampsia
ACTRN12625001416482Phase 3Withdrawn
- Sponsor
- Concept Foundation
- Start
- Oct 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 4
01
Overview
Phase 3, randomised trial of aspirin in preeclampsia (2 arms), sponsored by Concept Foundation. Primary endpoints: Birth with preeclampsia before 37 weeks' gestation and Composite outcome on use of additional interventions for management of postpartum haemorrhage. Planned start Oct 2026; status: withdrawn.
02
Drugs
aspirin
03
Conditions
preeclampsia
Beyond the preview
Go deeper on ACTRN12625001416482.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12625001416482.